HLN vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at HLN and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
HLN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RGC is a standard domestic listing.
| Symbol | HLN | RGC |
|---|---|---|
| Company Name | Haleon plc | Regencell Bioscience Holdings Limited |
| Country | United Kingdom | Hong Kong |
| GICS Sector | Consumer Staples | Health Care |
| GICS Industry | Personal Care Products | Pharmaceuticals |
| Market Capitalization | 43.48 billion USD | 6.64 billion USD |
| Exchange | NYSE | NasdaqCM |
| Listing Date | July 25, 2022 | July 16, 2021 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of HLN and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | HLN | RGC |
|---|---|---|
| 5-Day Price Return | 1.98% | 6.67% |
| 13-Week Price Return | -10.35% | 39.56% |
| 26-Week Price Return | -6.08% | 13,340.00% |
| 52-Week Price Return | -5.03% | 3,740.00% |
| Month-to-Date Return | -1.25% | 1.82% |
| Year-to-Date Return | -5.94% | 10,238.46% |
| 10-Day Avg. Volume | 18.28M | 0.31M |
| 3-Month Avg. Volume | 18.67M | 2.51M |
| 3-Month Volatility | 16.25% | 664.33% |
| Beta | 0.35 | 2.35 |
Profitability
Return on Equity (TTM)
HLN
3.26%
Personal Care Products Industry
- Max
- 31.59%
- Q3
- 20.42%
- Median
- 11.01%
- Q1
- 3.26%
- Min
- -18.42%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
HLN
12.84%
Personal Care Products Industry
- Max
- 15.12%
- Q3
- 12.06%
- Median
- 9.26%
- Q1
- 5.50%
- Min
- -0.40%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
RGC
--
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
HLN
19.64%
Personal Care Products Industry
- Max
- 19.80%
- Q3
- 17.96%
- Median
- 13.14%
- Q1
- 7.58%
- Min
- -4.25%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RGC
--
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
| Symbol | HLN | RGC |
|---|---|---|
| Return on Equity (TTM) | 3.26% | -54.75% |
| Return on Assets (TTM) | 1.58% | -51.38% |
| Net Profit Margin (TTM) | 12.84% | -- |
| Operating Profit Margin (TTM) | 19.64% | -- |
| Gross Profit Margin (TTM) | 60.75% | -- |
Financial Strength
Current Ratio (MRQ)
HLN
0.87
Personal Care Products Industry
- Max
- 4.26
- Q3
- 2.61
- Median
- 1.74
- Q1
- 1.13
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
HLN
0.53
Personal Care Products Industry
- Max
- 1.13
- Q3
- 0.63
- Median
- 0.26
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RGC
0.00
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -1.93
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
| Symbol | HLN | RGC |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 42.68 |
| Quick Ratio (MRQ) | 0.63 | 41.89 |
| Debt-to-Equity Ratio (MRQ) | 0.53 | 0.00 |
| Interest Coverage Ratio (TTM) | 8.00 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
HLN
0.72%
Personal Care Products Industry
- Max
- 4.08%
- Q3
- 2.46%
- Median
- 1.82%
- Q1
- 0.83%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
HLN
954.40%
Personal Care Products Industry
- Max
- 207.61%
- Q3
- 115.17%
- Median
- 69.37%
- Q1
- 47.71%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | HLN | RGC |
|---|---|---|
| Dividend Yield (TTM) | 0.72% | 0.00% |
| Dividend Payout Ratio (TTM) | 954.40% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
HLN
22.09
Personal Care Products Industry
- Max
- 55.49
- Q3
- 36.75
- Median
- 26.49
- Q1
- 22.40
- Min
- 11.12
In the lower quartile for the Personal Care Products industry, HLN’s P/E Ratio of 22.09 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
RGC
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
HLN
2.84
Personal Care Products Industry
- Max
- 5.35
- Q3
- 2.83
- Median
- 2.07
- Q1
- 1.13
- Min
- 0.00
HLN’s P/S Ratio of 2.84 is in the upper echelon for the Personal Care Products industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
RGC
--
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
HLN
2.11
Personal Care Products Industry
- Max
- 7.32
- Q3
- 5.26
- Median
- 2.93
- Q1
- 1.84
- Min
- 1.14
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | HLN | RGC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 22.09 | -- |
| Price-to-Sales Ratio (TTM) | 2.84 | -- |
| Price-to-Book Ratio (MRQ) | 2.11 | 9.57 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.81 | -- |